The study, published in Cancer Discovery, pinpoints a specific change in the BTK gene—known as BTK A428D—as a potent “pan-resistance” mechanism. Importantly, the authors report that this mutation undermines therapeutic strategies across multiple drug classes that aim to disrupt BTK-dependent signaling.

BTK inhibitors work by binding to the BTK protein, blocking signals that cancer cells rely on for growth and survival. BTK degraders take a different approach: rather than simply blocking BTK activity, they recruit cellular machinery to eliminate the BTK protein. Previous laboratory findings suggested that the most common resistance mutations to inhibitors might remain vulnerable to degraders, setting up an expectation that degraders could broaden durability.

Using molecular, biochemical, and structural analyses, the researchers show that A428D forces the BTK protein into an altered three-dimensional conformation. In that reshaped state, drugs cannot attach effectively, explaining why both inhibitor binding and degrader-based targeting fail. “The surprising part was that the BTK A428D has a completely different conformation that makes it impossible for any drugs to bind to it,” said co-author Justin Taylor, M.D.

The team also describes a biological tradeoff: the mutation reduces cancer-cell fitness. That constraint may help explain why A428D is observed more often in patients treated with BTK degraders than in those receiving inhibitors alone.

Beyond diagnosis of the problem, the study explores prevention. In preclinical models, combining BTK degraders with a different drug class that targets the BCL2 protein prevented the emergence of resistant cancer cells. This supports further testing of combination strategies designed to keep tumors from evolving escape routes.

While A428D accounts for resistance in some patients, not all progressed cases share the mutation, indicating additional mechanisms remain to be discovered. Still, the new structural blueprint offers a roadmap for identifying at-risk patients and designing therapies that can bypass or neutralize resistance.

Overall, the findings highlight a viral-newsworthy message for targeted oncology: cancer evolution can outmaneuver even next-generation drugs, but structural insight may help clinicians stay several steps ahead.

Subject of Research: CLL and other B-cell malignancies; resistance to BTK inhibitors and BTK degraders
Article Title: Molecular and Structural Basis of Pan-Resistance to BTK Degraders and Inhibitors
News Publication Date: 22-Jul-2026
Web References: https://aacrjournals.org/cancerdiscovery/article/doi/10.1158/2159-8290.CD-26-0251/786984/Molecular-and-Structural-Basis-of-Pan-Resistance
References: 10.1158/2159-8290.CD-26-0251
Image Credits: Sylvester Comprehensive Cancer Center

Keywords: BTK, BTK degraders, BTK inhibitors, chronic lymphocytic leukemia, drug resistance, structural biology, A428D mutation, Cancer Discovery, targeted therapy, BCL2

AML is a devastating hematologic malignancy characterized by the rapid growth of abnormal white blood cells in the bone marrow, interfering with normal hematopoiesis. Among various genetic aberrations driving its aggressiveness, the internal tandem duplication (ITD) mutation in the FLT3 gene is associated with particularly poor prognosis. While targeted therapies, such as FLT3 inhibitors, have improved outcomes, resistance invariably arises, complicating long-term management. Cabozantinib, which inhibits multiple kinases including FLT3, has shown promise but is no exception to resistance development.

The team’s research pivots on the hypothesis that metabolic reprogramming—a hallmark of cancer—plays a critical role in how AML cells escape cabozantinib’s cytotoxicity. Using sophisticated cell models of FLT3-ITD AML, they meticulously charted changes in metabolic pathways as cells acquired drug resistance. By integrating multi-omic analyses including transcriptomics, metabolomics, and proteomics, they painted a comprehensive picture of the metabolic adaptations fueling survival under therapeutic pressure.

One of the most striking findings of the study is the shift in energy metabolism characterized by an enhanced reliance on oxidative phosphorylation (OXPHOS). Whereas sensitive AML cells predominantly utilize glycolysis for their energy demands, resistant cells exhibited a metabolic switch, increasing mitochondrial respiration to meet their bioenergetic needs. This adaptation not only supports survival but also grants cells metabolic flexibility, rendering them less susceptible to cabozantinib’s inhibitory effects on proliferative signaling.

Moreover, the researchers identified a pivotal rewiring of amino acid metabolism, particularly glutamine metabolism, which fuels the tricarboxylic acid (TCA) cycle and maintains redox balance in resistant cells. This metabolic flux supports the synthesis of critical biomolecules and antioxidants, helping cells withstand oxidative stress induced by cabozantinib. Elevated glutaminase activity emerged as a hallmark of resistance, suggesting that targeting glutamine metabolism could sensitize cells to treatment.

Furthermore, lipid metabolism was found to be substantially altered. Resistant AML cells showed increased fatty acid oxidation (FAO), which contributes not only to energy production but also to membrane biosynthesis and signaling molecules crucial for survival signaling pathways. This expansion of FAO creates an alternative metabolic reservoir that maintains cell viability in the face of kinase inhibition.

Building upon these insights, the authors explored therapeutic avenues aimed at reversing resistance by modifying the metabolic landscape. Pharmacologic inhibition of mitochondrial complex I, glutaminase, and fatty acid oxidation enzymes displayed significant synergistic effects when combined with cabozantinib, restoring drug sensitivity and inducing apoptosis in resistant AML cells. These findings point toward a multi-pronged metabolic intervention strategy that could preclude or overcome resistance.

Interestingly, the study also underscores the interplay between oncogenic signaling and metabolic regulation. FLT3-ITD signaling not only drives proliferation but also orchestrates metabolic gene expression programs that enable the metabolic plasticity observed in resistant cells. Interrupting this crosstalk disrupts AML cells’ adaptive capacity, highlighting the interconnectedness of genetic and metabolic vulnerabilities.

Importantly, this research emphasizes the utility of integrating comprehensive metabolic profiling in preclinical models to unveil resistance mechanisms that might otherwise remain obscured in genomics-focused approaches. By unraveling the metabolic dependencies of resistant AML cells, the study sets the stage for personalized metabolic interventions tailored to patients’ evolving tumor biology.

The translational value of these findings is substantial. Given that cabozantinib and metabolic inhibitors are already in clinical use or trials for various cancers, this study lays a practical framework for rapid clinical translation. Combination regimens guided by metabolic biomarkers have the potential to delay or abolish resistance, thereby prolonging remissions and improving survival outcomes for patients with FLT3-ITD AML.

Future research is warranted to evaluate the safety and efficacy of these metabolic combinations in vivo and in clinical trials. Equally important is the development of robust metabolic biomarkers to identify patients at risk of developing resistance and to monitor metabolic shifts during therapy. Such dynamic assessment will enhance the precision of therapeutic interventions and minimize unnecessary toxicities.

Finally, this study redefines our understanding of drug resistance in AML as a multifaceted phenomenon governed not only by genetic mutations but also by adaptive metabolic networks. Therapeutic strategies that incorporate metabolism-centric insights are poised to transform AML treatment and inspire analogous approaches in other malignancies characterized by targeted therapy resistance.

The pioneering work by Fu et al. demonstrates that it is possible to outmaneuver AML cells’ cunning metabolic reprogramming through strategic modulation of their metabolic signatures. This offers a beacon of hope for patients battling resistant AML, underscoring the power of deep mechanistic understanding to unlock new horizons in cancer therapy.

Subject of Research:
Acute myeloid leukemia (AML) with FLT3-ITD mutations and mechanisms of cabozantinib resistance.

Article Title:
Modulating metabolic signatures to mitigate cabozantinib resistance in FLT3-ITD acute myeloid leukemia cell models.

Article References:
Fu, YH., Ng, K.M., Tseng, CY. et al. Modulating metabolic signatures to mitigate cabozantinib resistance in FLT3-ITD acute myeloid leukemia cell models. Cell Death Discov. (2026). https://doi.org/10.1038/s41420-026-02957-8

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s41420-026-02957-8